AQST
Aquestive Therapeutics' first quarter revenue grew 66% as it reaffirms plans for a third quarter 2026 Anaphylm NDA resubmission.
Aquestive Therapeutics reported first quarter 2026 revenue of $14.4 million, a 66% increase from the prior year, and a net loss per share of $0.07. The company...
